ID: h-var-4ae5ef95fa
Hypothesis

Plasma TREM2 Ectodomain Glycosylation Patterns as Microglial Senescence Biomarker

Site-specific glycosylation patterns on circulating TREM2 ectodomain fragments distinguish senescent from activated microglia states in neurodegeneration.
🧬 TREM2/ST6GAL1/MGAT5🩺 biomarkers🎯 Composite 38%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 3 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.70 (15%) Evidence 0.27 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.88 (10%) Safety 0.85 (8%) Competition 0.70 (6%) Data Avail. 0.50 (5%) Reproducible 0.52 (5%) KG Connect 0.50 (8%) 0.380 composite

🧪 Overview

Site-specific glycosylation patterns on circulating TREM2 ectodomain fragments distinguish senescent from activated microglia states in neurodegeneration. Unlike proteolytic cleavage ratios, this approach leverages differential glycosyltransferase activity (ST6GAL1, MGAT5) that occurs during microglial senescence transitions. Senescent microglia exhibit altered N-linked glycan branching and sialylation on TREM2 before ectodomain shedding, creating distinct glycoform signatures detectable in plasma rather than CSF. The mechanism centers on age-related shifts in ER glycosylation machinery that precede ADAM-mediated shedding, making glycoform analysis upstream of proteolytic processing. This plasma-based assay offers superior clinical accessibility compared to CSF sampling while providing mechanistic insight into microglial aging processes that drive neurodegeneration. Glycan analysis by lectin arrays or mass spectrometry could distinguish homeostatic surveillance (high-mannose, low-sialic acid) from senescence-associated secretory phenotype microglia (complex branched, hypersialylated).

...

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["TREM2/ADAM10/17<br/>Primary Target"]
    B["Biological Process 1<br/>Mechanistic Step A"]
    C["Biological Process 2<br/>Mechanistic Step B"]
    D["Output Phenotype<br/>Disease Effect"]
    A --> B
    B --> C
    C --> D
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix3 supports2 contradicts
Supports
CSF sTREM2 increases in early symptomatic AD
Supports
TREM2 variants alter microglial response to amyloid plaques
Supports
TREM2 is high-value target with active development programs (Biogen, AbbVie, Denali)
Contradicts
Proposed mass spectrometry assay for site-specific fragments does not exist; requires 1-2 years development
Contradicts
Biphasic sTREM2 pattern adds temporal complexity; fragment ratio mapping to priming states unestablished
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — TREM2

🧬 PDB 6YXY Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TREM2/ST6GAL1/MGAT5 from GTEx v10.

Spinal cord cervical c-148.4 Substantia nigra20.7 Hypothalamus10.9 Hippocampus9.8 Amygdala8.9 Caudate basal ganglia7.9 Putamen basal ganglia6.6 Nucleus accumbens basal ganglia6.2 Anterior cingulate cortex BA245.6 Frontal Cortex BA95.1 Cortex3.5 Cerebellar Hemisphere2.9 Cerebellum1.5median TPM (GTEx v10)

💉 Clinical Trials (1)

0
Active
0
Completed
0
Total Enrolled
Unknown·

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TREM2 →

No DepMap CRISPR Chronos data found for TREM2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0

💾 Resource Usage

LLM Tokens
25,530
$0.0766
Total Cost
$0.0766
Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
sourcev1_phase_c_backfill
origin_typedebate_synthesizer
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.